Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452969 | 0.91 | ROCK2 (0.53) | USP30DYRK1AGSK3BROCK2PARP1 | |
| SCHEMBL19902593 | 0.91 | USP30 (0.54) | USP30DYRK1AGSK3BROCK2RIPK2 | |
| SCHEMBL19902428 | 0.88 | USP30 (0.44) | USP30DYRK1AGSK3BROCK2PARP1 | |
| SCHEMBL19902531 | 0.88 | USP30 (0.43) | USP30DYRK1AGSK3BROCK2PARP1 | |
| SCHEMBL19902726 | 0.87 | USP30 (0.43) | USP30DYRK1AGSK3BROCK2PARP1 | |
| SCHEMBL19902373 | 0.84 | ROCK1 (0.51) | USP30DYRK1AGSK3BROCK2RIPK2 | |
| SCHEMBL17452932 | 0.82 | ROCK2 (0.55) | USP30DYRK1AGSK3BROCK2RIPK2 | |
| SCHEMBL19902646 | 0.80 | USP30 (0.55) | USP30ROCK2RIPK2CCNCCDK8 | |
| SCHEMBL17452951 | 0.80 | ROCK2 (0.55) | USP30DYRK1AGSK3BROCK2PARP1 | |
| SCHEMBL17452973 | 0.80 | ROCK2 (0.51) | USP30DYRK1AGSK3BROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885DYRK1A 874/4885GSK3B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.